Nanoco Reorganizes R&D and Invests in New Technology Resources for Next Chapter of Growth
20.8.2025 15:30:00 CEST | Business Wire | Press Release
Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of quantum dots and other nanomaterials emanating from its technology platform, announces the appointment of a new Director of Technology, alongside new investments in its R&D organization, concurrent with upcoming retirement of its Founder and CTO.
Retirement of Dr. Nigel Pickett
Dr. Nigel Pickett, Nanoco’s founder, CTO and board member, has announced his pending retirement, effective August 19, 2025. Over the next six months, he will focus on long-term technology initiatives and will transition into an advisory role by February 2026.
Nigel co-founded Nanoco in 2000 and has worked with the company from a small startup affiliated with University of Manchester, to a recognized leader in Quantum Dot (QD) technology, a vibrant organization with 350 patents making significant contributions to commercial applications of QDs in industries as diverse as Display, Image Sensor, Lighting, and Photovoltaic, among others.
Jalal Bagherli, CBE, Nanoco’s Chairman of the Board, commented:
“Nigel has made a significant contribution to Nanoco since its founding – the company was his life for the last quarter century. Because of Nigel’s resourcefulness and ingenuity, Nanoco is now a leader in its field. We wish Nigel all the best in his well-deserved retirement.”
Nanoco’s Technology leadership
Concurrent with Dr. Pickett’s retirement, Nanoco announced several promotions in its R&D organization.
Dr. Ombretta Masala, previously serving as Section Head, Nanomaterials, is assuming the role of Director of Technology, reporting to Nanoco’s CEO Dmitry Shashkov. Dr. Masala has worked with Nanoco for nearly 20 years.
In recognition of his outstanding technical expertise, Dr. James Harris has expanded his current role to become Head of QD Technologies.
Dr. Parthiban Ramasamy has been promoted to the position of Lead Scientist, focusing his work on Image Sensor development.
Dmitry Shashkov, Nanoco’s CEO, commented:
“Under Nigel’s leadership, the next generation of technology leaders have grown within the Company who are ready to lead Nanoco’s Technology team through our next chapter of growth. With significant experience, Ombretta is the right person for the job. Since the launch of our new strategy in October, Nanoco has formed and strengthened several technical collaborations, all stemming from our strong reputation for QD technology development. I want to congratulate Ombretta, James and Parthiban with their expanded roles.”
Investment in additional Technology resources
Nanoco also announced several new hires into its R&D organization, further strengthening its technology talent base.
Dr. Teoman Taskesen has joined Nanoco as Device Physicist. Teo joins the company after his previous 5-year tenure at Oxford Photovoltaics. Prior to that, he has had a successful international career in both academic and industrial settings related to Semiconductors, Quantum Dots and Photovoltaics (PV) in Turkey, Estonia and Germany.
Dr. Rounak Naphade has joined Nanoco as Senior Chemist. Rounak comes to the company from University of Chicago, where for the last two years he worked on Quantum Dot (QD) development for infrared image sensors in the world-renowned lab of Prof. Philippe Guyot-Sionnest. Prior to University of Chicago, Rounak conducted doctoral and post-doctoral QD research in well-known academic centers in Saudi Arabia and India.
Dr. Asim Önal has also joined the company as Senior Chemist. Asim comes to Nanoco after completing his PhD in Koc University in Istanbul, where he focused on development of QDs for Lighting, Display, and Biomedical applications. Prior to his PhD, Asim completed more than 5 years of undergraduate and graduate-level QD research in Turkey and Germany.
Dr. Ombretta Masala, Nanoco’s newly appointed Director of Technology, commented:
“We welcome Teo, Rounak, and Asim to Nanoco. Our growth and our reputation as a company depend on our team. All of our new hires come from distinguished technical backgrounds and bring their unique expertise to the company – we are delighted to expand our technology team with such strong, international talent.”
Notes for editors:
About Nanoco Group plc
Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium free quantum dots (CFQD® materials) and other patented nanomaterials for use in the electronics industries. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside its existing scaled up production facilities for commercial orders.
Nanomaterials are materials with dimensions typically in the range 1 - 100 nm. Nanomaterials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nanomaterial that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE® quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectra, rendering them useful for applications including cameras and image sensors.
Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250820925339/en/
Contacts
Nanoco Group plc:
Dmitry Shashkov, CEO
Liam Gray, CFO & Company Secretary
+44 (0)1928 761 404
Sodali & Co (Public Relations):
Elly Williamson
Pete Lambie
Oliver Banks
+44 (0)79 3535 1934
Nanoco@sodali.com
Cavendish Capital Markets Limited (Financial Adviser and Corporate Broker):
Ed Frisby / George Lawson (Corporate Finance)
Tim Redfern (Corporate Broking)
Jasper Berry (Sales)
+44 (0) 20 7220 0500
CDX Advisors (Strategic Adviser):
Steven Foland
Steve Month
Patrick Foley
+1 415 425 2224
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom